EGFR and glioblastoma: Mechanistic target of rapamycin complex 2 (mTORC2) plays a role in the DNA hypomethylator phenotype in GBM, particularly in tumors with platelet-derived growth factor receptor (PDGFR) amplification or the gain-of-function EGFR mutation, EGFRvIII.